



ASX RELEASE

Prof Martin Tallman joins Race scientific advisory team

12 December 2016, Perth, Australia: Race Oncology Ltd (ASX: RAC) announced today that Professor Martin Tallman MD, a leading international oncologist and expert in AML (Acute Myeloid Leukaemia) has joined Race Oncology's scientific advisory board.

Dr Tallman is Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York and a world-recognised expert in AML. Dr Tallman recently gave the keynote presentation on the treatment of AML at the ASH (American Society of Hematology) conference on haematological malignancies in Chicago.

He is also Professor of Medicine at Weill Cornell Medical College in New York and an Executive Committee Member of ASH. For more than 16 years, he has served as Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group (ECOG), one of only three major cooperative oncology groups in the US responsible for coordinating large clinical trials of new therapies for acute and chronic leukemias. Previously, he was on the faculty of Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center for more than 20 years, where he directed the Leukemia Program, was Co-Director of the Hematologic Malignancy Program at the Robert H. Lurie Comprehensive Cancer Center and was Associate Chief of the Division of Hematology-Oncology.

"Our board of scientific advisors now has three outstanding US key opinion leaders in AML," said Race Oncology CEO, Peter Molloy. "Dr Tallman is a highly-respected world-leader in the treatment of AML and we are privileged to have him on board." Dr Tallman joins Dr Douglas Smith (Johns Hopkins University) and Dr Roland Walter (Fred Hutchinson Cancer Research Center) in providing guidance for the ongoing clinical development of Bisantrene in relapsed/refractory AML.

About Race Oncology

Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit raceoncology.com for more information.

For more information, contact:

Peter Molloy
Managing Director

T: +61 (0) 3 9097 1656
M: plmolloy@raceoncology.com